PhosphoSolutions

894 products

Showing 265 - 288 of 894 products
View
Western blot analysis of human umbilical vein endothelial cells before (lanes 1, 3, 5) and after (lanes 2, 4, 6) treatment with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).Immunocytochemical labeling of endothelial nitric oxide synthase (eNOS) in paraformaldehyde-fixed and NP-40-permeabilized human umbilical vein endothelial cells. The cells were labeled with mouse monoclonal eNOS (NM2211) and rabbit polyclonal eNOS (NP2281) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.
Western blot analysis of human umbilical vein endothelial cells treated with calyculin A (100 nM) for 30 min. (lanes 1, 3, 5 & 7) then the blots were treated with lambda phosphatase (lanes 2, 4, 6 & 8). The blots were probed with anti-endothelial nitric oxide synthase (eNOS) (C-terminal region) (lanes 1 & 2), anti-eNOS (Ser-632) (lanes 3 & 4), anti-eNOS (Ser-1177) (lanes 5 & 6) and anti-eNOS (a.a. 1172-1181) (lanes 7 & 8).
Western blot analysis of human umbilical vein endothelial cells before (lanes 1, 3, 5) and after (lanes 2, 4, 6) treatment with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).Immunocytochemical labeling of endothelial nitric oxide synthase (eNOS) in paraformaldehyde-fixed and NP-40-permeabilized human umbilical vein endothelial cells. The cells were labeled with mouse monoclonal eNOS (NM2211) and rabbit polyclonal eNOS (NP2281) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.
Western blot analysis of human umbilical vein endothelial cells untreated (lanes 1, 3, 5, & 7) or treated with pervanadate (1 mM) for 30 min. (lanes 2, 4, 6, & 8). The blot was probed with anti-EphA4 (N-terminal region) (lanes 1 & 2), anti-EphA4 (Tyr-779) (lanes 3 & 4), anti-EphA4 (Tyr-602) (lanes 5 & 6), or anti-EphA4 (C-terminal region) (lanes 7 & 8).
Western blot analysis of human umbilical vein endothelial cells untreated (lanes 1, 3, 5, & 7) or treated with pervanadate (1 mM) for 30 min. (lanes 2, 4, 6, & 8). The blot was probed with anti-EphA4 (N-terminal region) (lanes 1 & 2), anti-EphA4 (Tyr-779) (lanes 3 & 4), anti-EphA4 (Tyr-602) (lanes 5 & 6), or anti-EphA4 (C-terminal region) (lanes 7 & 8).Western blot image of various mouse and human HCC cell lines expressing EphA4 (Cat no EM2801, 1:1000). Image from publication CC-BY-4.0. PMID: 38307859
Western blot analysis of human A431 epithelial cells untreated (lanes 1 & 4) or treated with 100 nM calyculin A for 30 min. (lanes 2 & 5) or 100 ng/ml EGF for 60 min. (lanes 3 & 6). The blots were probed with anti-ERK1 (C-terminal region) (lanes 1, 2, & 3) or anti-ERK1/2 (Thr-202/Tyr-204) (lanes 4, 5, & 6).Immunocytochemical labeling of ERK1 in paraformaldehyde-fixed and NP-40-permeabilized rabbit spleen fibroblasts. The cells were labeled with mouse monoclonal ERK1 (C-terminal region) and detected using appropriate secondary antibodies conjugated to Cy3.

Recently Viewed